Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;46(4):163-171.
doi: 10.5535/arm.22061. Epub 2022 Aug 31.

Efficacy and Safety of Botulinum Toxin Type A (NABOTA) for Post-stroke Upper Extremity Spasticity: A Multicenter Phase IV Trial

Wonjae Hwang  1 , Seong Min Kang  1 , Sang Yoon Lee  2 , Han Gil Seo  1 , Yoon Ghil Park  3 , Bum Sun Kwon  4 , Kwang Jae Lee  5 , Deog Young Kim  6 , Hyoung Seop Kim  7 , Shi-Uk Lee  2
Affiliations

Efficacy and Safety of Botulinum Toxin Type A (NABOTA) for Post-stroke Upper Extremity Spasticity: A Multicenter Phase IV Trial

Wonjae Hwang et al. Ann Rehabil Med. 2022 Aug.

Abstract

Objective: To evaluate the efficacy and safety of Daewoong botulinum toxin type A (NABOTA) after its launch in South Korea.

Methods: This prospective, multicenter, open-label phase IV clinical trial included 222 patients with stroke. All patients visited the clinic at baseline and at weeks 4, 8, and 12 after injection of upto 360 units of NABOTA into the wrist, elbow, and finger flexor muscles at the first visit. The primary outcome was the change in Modified Ashworth Scale (MAS) score for the wrist flexor muscles between baseline and week 4. The secondary outcomes were the changes in MAS, Disability Assessment Scale (DAS), and Caregiver Burden Scale (CBS) scores between baseline and each visit, and the Global Assessment Scale (GAS) score at week 12.

Results: There was a statistically significant decrease in the MAS score for the wrist flexors between baseline and week 4 (-0.97±0.66, p<0.001). Compared with baseline, the MAS, DAS and CBS scores improved significantly during the study period. The GAS was rated as very good or good by 86.8% of physicians and by 60.0% of patients (or caregivers). The incidence of adverse events was 14.4%, which is smaller than that in a previous trial.

Conclusion: NABOTA showed considerable efficacy and safety in the management of upper limb spasticity in stroke patients.

Keywords: Botulinum toxin type A; Clinical trial; Muscle spasticity; Phase 4; Safety; Stroke; Treatment efficacy.

PubMed Disclaimer

Conflict of interest statement

The corresponding author of this manuscript is an editor of Annals of Rehabilitation Medicine. The corresponding author did not engage in any part of the review and decision-making process for this manuscript.

Figures

Fig. 1
Fig. 1
Flow chart showing the patient enrollment process.
Fig. 2
Fig. 2
Modified Ashworth Scale (MAS) scores for the wrist, elbow, and finger flexor muscles at baseline and at 4, 8, and 12 weeks post-injection for the full analysis set. Values are shown as mean±standard deviation. ***p<0.001 (post-hoc Wilcoxon signed-rank test adjusted by Bonferroni correction).
Fig. 3
Fig. 3
Disability Assessment Scale (DAS) score in each domain at baseline and at 4, 8, and 12 weeks post-injection for the full analysis set. Values are shown as the mean±standard deviation. **p<0.01, ***p<0.001 (post-hoc Wilcoxon signed-rank test adjusted by Bonferroni correction).
Fig. 4
Fig. 4
Caregiver Burden Scale (CBS) score in each domain at baseline and at 4, 8, and 12 weeks post-injection for the full analysis set. Values are shown as the mean±standard deviation. *p<0.05, **p<0.01, ***p<0.001 (post-hoc Wilcoxon signed-rank test adjusted by Bonferroni correction).
Fig. 5
Fig. 5
Global Assessment Scale (GAS) score rated by the physician or patient/caregiver at 12 weeks post-injection for the full analysis set.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Jung SH. Stroke rehabilitation fact sheet in Korea. Ann Rehabil Med. 2022;46:1–8. - PMC - PubMed
    1. Kuo CL, Hu GC. Post-stroke spasticity: a review of epidemiology, pathophysiology, and treatments. Int J Gerontol. 2018;12:280–4.
    1. Sunnerhagen KS, Olver J, Francisco GE. Assessing and treating functional impairment in poststroke spasticity. Neurology. 2013;80(3 Suppl 2):S35–44. - PubMed
    1. Kim CS, Song KY, Min KM, An YD, inventors. Method for production of botulinum toxin. 2015/016462 (KR2014/004003) World patent WO. 2015 Feb 5;
    1. Kim CS, Jang WS, Son IP, Nam SH, Kim YI, Park KY, et al. Electrophysiological study for comparing the effect of biological activity between type A botulinum toxins in rat gastrocnemius muscle. Hum Exp Toxicol. 2013;32:914–20. - PubMed

LinkOut - more resources